key: cord-1023237-wngq1u88
authors: Martinot, Martin
title: Should remdesivir be recommended in France in the early stage of COVID-19
date: 2022-01-02
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.359
sha: 8da81f5c3544fcf9ea0d50ae4df822349487035f
doc_id: 1023237
cord_uid: wngq1u88

nan

 Due to the Discovery trial French recommendations do not include remdesivir.

 New COVID-19 variants are responsible of high viral loads and antivirals are lacking.

 Following the ESCMID guidelines, remdesivir should be re-evaluated in France. , due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a raging pandemic. Remdesivir, an RNA-dependent RNA polymerase (RdRP) inhibitor, was the first antiviral drug to be approved for SARS-CoV-2 in the USA (Beigel et al., 2020) and Europe (European Medicine Agency, 2020) and affects the hospital length of stay but not mortality (Goldman et al., 2020) . The Solidarity and Discovery trials did not find clinical benefit from the use of remdesivir in COVID-19 treatment (Ader et al., 2021 , Consortium et al., 2021 .

However, most patients included in these trials admitted to hospital for COVID-19, were symptomatic for >7 days and required oxygen support at a time where the inflammatory process is predominant and antiviral drugs are less efficient.

The authors of the Discovery study limited their conclusion to symptomatic patients who were hospitalized for >7 days and required oxygen support. Note that numerous guidelines still include remdesivir in their strategy, such as the Infectious FundingThe authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare that this report does not contain any personal information that could lead to their identification.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, openlabel trial

ESCMID COVID-19 Living guidelines: drug treatment and clinical management

Remdesivir for the Treatment of Covid-19 -Final Report

Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

First COVID-19 treatment recommended for EU authorisation

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

Guidelines on the Treatment and Management of Patients with COVID-19

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease

The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study

The authors have no conflicts of interest to report.